12 completed, 2 terminated, 1 active not recruiting, 1 unknown. 13 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Progesterone Receptor-negative Breast Cancer: new trials by email Literature Review of Progesterone Receptor-negative Breast Cancer trials Research Report on Progesterone Receptor-negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 62 | 2015-02-25 | 2023-03-29 |
| MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Breast surgery, Magnetic resonance imaging, Mammography - Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 319 | 2014-05-21 | 2026-06-26 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Paclitaxel, Carboplatin, Doxorubicin - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2013-04-25 | 2025-04-30 |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients eribulin mesylate, carboplatin, biopsy - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Unknown | Northwestern University | 30 | 2011-08-01 | 2019-06-07 |
| Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery entinostat, anastrozole, diagnostic laboratory biomarker analysis - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | University of Maryland, Baltimore | 5 | 2010-10-01 | 2022-05-03 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer veliparib, cisplatin, vinorelbine tartrate - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Completed | University of Washington | 50 | 2010-07-01 | 2017-08-10 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2010-06-01 | 2017-04-11 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer external beam radiation therapy, questionnaire administration, therapeutic conventional surgery - Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2010-02-01 | 2011-12-08 | |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PD-0332991 - Adult Solid Tumor, Adenocarcinoma of the Colon | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 304 | 2009-10-01 | 2021-03-11 |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography - Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2008-09-01 | 2020-02-19 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Completed | University of Washington | 59 | 2008-04-23 | 2018-12-04 |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery saracatinib, laboratory biomarker analysis - Estrogen Receptor-negative Breast Cancer, Male Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2007-10-01 | 2014-04-30 |
| Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate - Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer | Phase 2 | Completed | Indiana University | 30 | 2007-07-01 | 2023-10-16 |
| Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer placebo, quality-of-life assessment, questionnaire administration - Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2007-07-01 | 2014-09-12 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery doxorubicin hydrochloride, cyclophosphamide, paclitaxel - Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer | Phase 2 | Completed | University of Washington | 50 | 2003-10-01 | 2018-03-12 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2001-12-01 | 2013-09-30 |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer tamoxifen citrate, busulfan, thiotepa - Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer | Phase 2 | Completed | Fred Hutchinson Cancer Center | 50 | 1997-11-01 | 2017-07-12 |
Breast Neoplasms (17) · Triple Negative Breast Neoplasms (9) · Breast Neoplasms, Male (7) · Colonic Neoplasms (2) · Rectal Neoplasms (2) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Bile Duct Neoplasms (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Lobular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1)
Breast Diseases (17) · Neoplasms (17) · Neoplasms by Site (17) · Skin Diseases (17) · Skin and Connective Tissue Diseases (17) · Neoplasms by Histologic Type (3) · Adenocarcinoma (2) · Carcinoma (2) · Colonic Diseases (2) · Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gastrointestinal Diseases (2)
Carboplatin (3) · Cyclophosphamide (3) · Paclitaxel (3) · Taxes (3) · Albumin-Bound Paclitaxel (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Mastectomy, Segmental (2) · Methotrexate (2) · Tamoxifen (2) · Vinorelbine (2) · liposomal doxorubicin (2) · veliparib (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)
National Cancer Institute (NCI) (5) · University of Washington (3) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Case Comprehensive Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Indiana University (1) · Northwestern University (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Maryland, Baltimore (1)
United States (16) · Canada (1)
Jennifer Specht (2) · Clifford Hudis (1) · David A Mankoff, MD, PhD (1) · Dawn Hershman (1) · Edith Mitchell, MD (1) · Georgiana Ellis (1) · Isabelle Bedrosian, MD (1) · Janet F Eary, MD (1) · Kathy Miller, MD (1) · Kim Hirshfield (1) · Leona A Holmberg (1) · Paula Fracasso (1) · Peter ODwyer (1) · Saranya Chumsri (1) · Srikala Sridhar (1)
PMID 22827973, PMID 24170452, PMID 26006067, PMID 26059540, PMID 32641862, PMID 32692450
P30CA015704 (2), N01CM00032 (1), N01CM62204 (1), N01CM62206 (1), N01CN35159 (1), P30CA016672 (1), P30CA044579 (1), P30CA072720 (1), U10CA037447 (1)